No­var­tis part­ner Ar­tios bags megaround to dri­ve clin­i­cal work on DNA dam­age re­pair fac­tors

Bio­phar­ma is con­stant­ly on the hunt for the next gen­er­a­tion of tar­get­ed on­col­o­gy drugs to ef­fec­tive­ly wipe out can­cer cells. But to keep those tu­mors gone, biotechs like Ar­tios, now the re­cip­i­ent of a fundrais­ing megaround, are us­ing the cells’ own dam­age re­pair mech­a­nisms against them.

Ar­tios Phar­ma has snagged a $153 mil­lion C round to help dri­ve the UK-based biotech’s lead can­di­dates tar­get­ing DNA dam­age re­pair fac­tors — pro­teins that help knit to­geth­er dam­aged DNA — through the clin­ic, the biotech said Tues­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER